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Abstract
Background: Triglyceride concentrations are raised in pregnancy and are considered a key fetal
fuel. Several gene variants are known to alter triglyceride concentrations, including those in the
Apolipoprotein E (ApoE), Lipoprotein Lipase (LPL), and most recently, the Apolipoprotein AV (ApoAV)
gene. However, less is known about how variants in these genes alter triglyceride concentrations
in pregnancy or affect fetal growth. We aimed to determine the effect of the recently identified
ApoAV gene on triglycerides in pregnancy and fetal growth. We assessed the role of two ApoAV
haplotypes, defined by the C and W alleles of the -1131T>C and S19W polymorphisms, in 483
pregnant women and their offspring from the Exeter Family Study of Childhood Health.
Results: The -1131T>C and S19W variants have rare allele frequencies of 6.7% and 4.9% and are
present in 13.4% and 9.7% of subjects respectively. In carriers of the -1131C and 19W alleles
triglyceride concentrations were raised by 11.0% (1.98 mmol/ l(1.92 – 2.04) to 2.20 mmol/l (2.01
– 2.42), p = 0.035; and 16.2% (1.97 mmol/l (1.91 – 2.03) to 2.29 mmol/l (2.12 – 2.48), p < 0.001
respectively. There is nominally significant evidence that the -1131T>C variant is having an effect
on maternal height (164.9 cm (164.3 – 165.5) to 167.0 cm (165.2 – 168.8), p = 0.029). There was
no evidence that ApoAV genotype alters any other anthropometric measurements or
biochemistries such as High Density Lipoprotein Cholesterol (HDL-C) or Low Density Lipoprotein
Cholesterol (LDL-C). There is nominally significant evidence that the presence of a maternal -
1131C variant alters fetal birth length (50.2 cm (50.0 – 50.4) to 50.9 cm (50.3 – 51.4), p = 0.022),
and fetal birth crown-rump length (34.0 cm (33.8 – 34.1) to 34.5 cm (34.1 – 35.0), p = 0.023). There
is no evidence that ApoAV genotype alters fetal birth weight or other fetal growth measurements.
Conclusion: In conclusion variation in the ApoAV gene raises triglyceride concentrations in
pregnancy, as well as normolipaemic states and there is preliminary evidence that it alters fetal
growth parameters.
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Background
Triglycerides are a key fetal fuel in pregnancy. Triglyceride
concentrations are raised in pregnancy due to the overpro-
duction of triglyceride rich very low-density lipoprotein
(VLDL) cholesterol [1]. Pregnancy also elevates total and
low-density lipoprotein (LDL) cholesterols [2] and lowers
high-density lipoprotein (HDL) cholesterol [1]. Triglycer-
ide concentrations increase gradually with the duration of
pregnancy with significant increases during the second tri-
mester [2]. Triglyceride and cholesterol concentrations
return to pre-pregnant concentrations 20–24 weeks post
partum [2], with a rapid reduction in triglycerides and
cholesterol in breast-feeding mothers compared to moth-
ers where lactation was never established [3].
Triglyceride and cholesterol concentrations are under
strong genetic control. Variants in several genes, includ-
ing, ApoE [1], LPL [1], LDL receptor [4], Apolipoprotein CIII
(ApoCIII) [5], Apolipoprotein AIV (ApoAIV) [5] and,
recently ApoAV [6] are associated with altered triglyceride
and cholesterol concentrations [7]. Despite this, little is
known about how these variants alter lipid profiles in
pregnancy. In one study of 250 pregnant females from a
number of ethnic groups, the genes encoding LPL (S447X
and N291S) and ApoE (E2 allele) are associated with
altered triglyceride and HDL-cholesterol concentrations
in pregnancy [1].
High triglyceride concentrations in pregnancy can result
in acute pancreatitis [8] and are associated with pre-
eclampsia [9]. In addition to these implications for mater-
nal health, maternal triglyceride concentrations are corre-
lated with offspring birth weight. This correlation is
independent of maternal pre-pregnant Body Mass Index
(BMI), maternal weight gain, fasting glucose, gender and
gestational age [10].
Common variation in the ApoAV gene has recently been
shown to have one of the largest effects on triglyceride
concentrations in the normal population. ApoAV was
recently discovered in the ApoAI/CIII and AIV gene cluster
using comparative genomics of human and mouse
genomes [6]. Studies on transgenic and knockout mice
showed that ApoAV is a key regulator of triglyceride con-
centrations in mice. In man, two haplotypes of the ApoAV
gene, each of ~6.0% frequency in caucasians and defined
by the C and W alleles of the -1131T>C and S19W single
nucleotide polymorphisms (SNP), are associated with
increased triglyceride concentrations. Male carriers of one
or two copies of the -1131C and 19W have triglyceride
concentrations ~40.0% higher than subjects homozygous
for the -1131T and 19S alleles [11]. There is less data avail-
able in women, but, a study of 442 caucasian women
from the Dallas Heart Disease Prevention Project
(DHDPP) showed an increase of 22.0% in carriers of
either the -1131C or 19W haplotypes [11]. In addition to
altering triglyceride concentrations, ApoAV variants have
been associated with VLDL-cholesterol (P = <0.001), but
not altered HDL-cholesterol or LDL-cholesterol concen-
trations [11]. Non-pregnant caucasian women were
shown to have triglycerides that were 23.0% (17.4% –
36.6%) lower than caucasian males [11], p < 0.05.
The -1131C allele raises triglyceride concentrations in a
variety of dyslipidaemic conditions such as hyperlipidae-
mia, hypoalphalipoproteinaemia and hyperalphalipo-
proteinaemia from the University of California, San
Francisco (UCSF) Genomic Resource in Arteriosclerosis
[7].
The chemical properties of Apolipoprotein AV indicate
that it may retard triglyceride-rich particle assembly and
may function intracellularly to modulate hepatic Very
Low Density Lipoprotein (VLDL) synthesis and/or secre-
tion [12]. The Apolipoprotein AV gene is only expressed
in the liver and has a very low plasma concentration.
ApoAV may therefore affect plasma triglyceride levels by
modulating hepatic VLDL assembly and secretion, rather
than the intravascular metabolism of triglyceride-rich
lipoproteins [12]. The -1131T>C polymorphism is in the
promoter region and may therefore affect transcription of
the ApoAV gene. The S19W polymorphism changes the
amino acid serine to a tryptophan at codon 19. This
change could alter the secondary structure of the protein
and alter protein folding, thus altering the function of the
protein.
The role of ApoAV gene variants in regulating triglyceride
concentrations in pregnancy is not known. To gain a bet-
ter understanding of the genetic control of triglycerides in
pregnancy and potential effects on fetal growth we have
examined the role of the variants -1131T>C and S19W in
the ApoAV gene in caucasian pregnant women and their
offspring. We have shown that two common variants in
the ApoAV gene alter triglycerides in pregnancy by 11.0%
(1.5% to 22.2%) and 16.2% (7.6% to 25.9%).
Results
Triglyceride concentrations in 483 pregnant females (2.01
mmol/l (1.96 – 2.06)) were higher than those in their
male partners (1.34 mmol/l (1.28 – 1.39), p value of
<0.001).
Both Single Nucleotide Polymorphisms (SNPs) were in
Hardy Weinberg Equilibrium. The frequencies of the two
rare alleles were 6.7% for -1131T>C and 4.9% for S19W.
Nine point seven percent of subjects are carriers of at least
one -1131C allele and 13.4% are carriers of at least one
19W allele with 0.6% carrying both a -1131C and a 19W
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allele. We did not observe any significant LD between the
two variants, D' = 0.33; p >0.5.
The -1131T>C and S19W ApoAV variants alter triglyceride 
concentrations in pregnancy
Tables 1 and 2 show the effect on maternal anthropome-
try and biochemistry for -1131T>C and S19W respec-
tively. Each of the two ApoAV variants was associated with
altered triglyceride concentrations in pregnancy. The two
SNPs increased triglycerides concentrations by a similar
magnitude of effect, the -1131C showed a 11.0% increase
(from 1.98 mmol/l (1.92 – 2.04) to 2.20 mmol/l (2.01 –
2.42), p = 0.035), and 19W a 16.2% increase (from 1.97
mmol/l (1.91 – 2.03) to 2.29 mmol/l (2.12 – 2.48), p <
0.001) respectively.
Table 1: The effect of ApoAV -1131T>C genotype in pregnancy:
Measurement TT (n = 436) TC (n = 47)* P Value
Age (Years) 30.32 (29.83 – 30.80) 32.21 (29.74 – 32.69) 0.26
Weight (kg) 74.64 (73.62 – 75.86) 78.34 (74.64 – 82.04) 0.06
Height (cm) 164.9 (164.3 – 165.5) 167.0 (165.2 – 168.8) 0.03
Head Circumference (cm) 55.7 (55.6 – 55.9) 56.0 (55.6 – 56.4) 0.34
Arm Circumference (cm) 28.8 (28.5 – 29.1) 29.9 (28.2 – 30.2) 0.49
Bicep (cm) 11.1 (10.7 – 11.5) 11.8 (10.5 – 13.3) 0.33
Triceps (cm) 21.7 (21.0 – 22.3) 21.6 (19.6 – 23.6) 0.97
Sub Scapular (cm) 21.9 (21.1 – 22.7) 23.1 (20.6 – 25.5) 0.39
% Body Fat 32.47 (32.00 – 32.93) 33.14 (31.71 – 34.56) 0.38
Sum Skin fold (cm) 52.5 (50.8 – 54.2) 54.7 (49.7 – 60.4) 0.43
Body Density 1.026 (1.025 – 1.027) 1.024 (1.021 – 1.027) 0.20
Fasting Glucose (mmol/l) 4.35 (4.31 – 4.38) 4.43 (4.33 – 4.53) 0.13
Fasting Total Cholesterol (mmol/l) 6.43 (6.31 – 6.53) 6.75 (6.40 – 7.11) 0.08
Fasting Triglycerides (mmol/l) 1.98 (1.92 – 2.04) 2.2 (2.01 – 2.42) 0.04
Fasting HDL-C (mmol/l) 1.98 (1.94 – 2.03) 2.07 (1.94 – 2.20) 0.20
Fasting LDL-C (mmol/l) 3.43 (3.33 – 3.53) 3.56 (3.25 – 3.89) 0.44
Fasting Total Cholesterol/Fasting HDL-C 3.33 (3.25 – 3.41) 3.3 (3.06 – 3.56) 0.85
Fasting HDL-C/Fasting LDL-C Ratio 0.48 (0.46 – 0.50) 0.5 (0.44 – 0.56) 0.67
*No rare homozygous subjects were identified
Table 2: The effect of ApoAV S19W genotype in pregnancy:
Measurement SS (n = 400) SW/WW (n = 62)* P Value
Age (Years) 30.38 (29.87 – 30.89) 30.1 (29.80 – 32.39) 0.31
Weight (kg) 75.51 (74.30 – 76.74) 73.11 (70.15 – 76.21) 0.15
Height (cm) 165.2 (164.6 – 165.8) 164.3 (162.8 – 165.9) 0.31
Head Circumference (cm) 55.9 (55.7 – 56.0) 55.6 (55.3 – 56.0) 0.44
Arm Circumference (cm) 28.9 (28.6 – 29.3) 28.6 (27.7 – 29.4) 0.42
Bicep (cm) 11.2 (10.7 – 11.8) 11.1 (10.0 – 12.4) 0.92
Triceps (cm) 21.9 (21.2 – 22.5) 21.5 (19.7 – 23.2) 0.71
Sub Scapular (cm) 22.3 (21.4 – 23.1) 21.2 (19.0 – 23.3) 0.35
% Body Fat 32.65 (32.16 – 33.14) 32.29 (31.05 – 33.54) 0.61
Sum Skin fold (cm) 53.1 (51.3 – 55.0) 51.8 (47.5 – 56.5) 0.60
Body Density 1.026 (1.025 – 1.027) 1.026 (1.024 – 1.029) 0.79
Fasting Glucose (mmol/l) 4.36 (4.32 – 4.39) 4.39 (4.30 – 4.48) 0.50
Fasting Total Cholesterol (mmol/l) 6.37 (6.27 – 6.49) 6.73 (6.44 – 7.05) 0.03
Fasting Triglycerides (mmol/l) 1.97 (1.91 – 2.03) 2.29 (2.12 – 2.48) <0.001
Fasting HDL-C (mmol/l) 1.97 (1.92 – 2.01) 2.06 (1.95 – 2.17) 0.11
Fasting LDL-C (mmol/l) 3.4 (3.30 – 3.51) 3.5 (3.24 – 3.78) 0.53
Fasting Total Cholesterol/Fasting HDL-C 3.33 (3.24 – 3.41) 3.35 (3.14 – 3.58) 0.84
Fasting HDL-C/Fasting LDL-C Ratio 0.48 (0.46 – 0.50) 0.48 (0.43 – 0.54) 0.97
*Includes one rare homozygous subject
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Total Cholesterol concentrations were raised in pregnant
females carrying at least 1 rare allele. Subjects with -1131C
allele had 6.75 mmol/l (6.40 – 7.11) compared to 6.43
mmol/l (6.31 – 6.53) in non carriers (p = 0.078). Subjects
with 19W had 6.73 mmol/l (6.44 – 7.05) compared to
6.37 mmol/l (6.27 – 6.49) in non carriers (p = 0.025). The
effect of the -1131T>C variant did not reach significance.
There is no evidence of an effect in any of the remaining
biochemistry concentrations for either of the
polymorphisms.
Subjects carrying at least one rare allele at -1131T>C were
3.7 kg heavier (p = 0.06) and 2.10 cm taller (p = 0.029)
than non carriers. There was no evidence for either geno-
type altering other anthropometric measures.
Triglyceride Concentrations in mothers and fetal growth
Table 3 shows the effect of maternal ApoAV -1131T>C gen-
otype on measures of fetal growth in 483 newborns. There
is evidence that maternal genotype alters fetal birth length
(from 50.2 cm (50.0 – 50.4) to 50.9 cm (50.3 – 51.4), p =
0.022) and birth crown-rump length (from 34.0 cm (33.8
– 34.1) to 34.5 cm (34.1 – 35.0), p = 0.02). There was no
evidence that maternal genotype alters other fetal growth
measurements.
Table 4 shows the effect of the maternal S19W genotype
on measures of fetal growth. There is no evidence of an
effect on any of the fetal growth measurements.
Discussion
We have shown that variation in the ApoAV gene alters
triglyceride concentrations in pregnancy. The two haplo-
types, defined in this study by the -1131T>C and S19W
SNPs, raise triglycerides by 11.0% (1.5% – 22.2%) and
16.2% (7.6% – 25.9%) respectively. The -1131T>C and
S19W alleles were previously shown to increase triglycer-
ide concentrations in non-pregnant caucasian females by
22.0% [11]. The -1131T>C variant therefore has a slightly
lower magnitude of effect on triglycerides in pregnancy as
it does outside pregnancy, although based on our 95%
confidence intervals we cannot exclude an effect as small
as 1.5% or as large as 22.2% for -1131T>C variant and as
small as 7.6% and 25.9% for the S19W variant. Women
carrying at least one of either the 19W or -1131C alleles
may therefore be at increased risk of complications from
Table 3: The effect of -1131T>C maternal genotype on Fetal Growth:
Measurement TT (n = 436) TC (n = 47)* P Value
Gestational Age (weeks) 40.11 (39.98 – 40.23) 40.26 (39.88 – 40.64) 0.45
Corrected Birth weight (grams) 3518.1 (3475.70 – 3560.49) 3589.65 (3460.77 – 3718.54) 0.3
Raw Birth weight (grams) 3535.6 (3493.01 – 3578.19) 3606.42 (3476.95 – 3735.88) 0.31
Birth Length (cm) 50.2 (50.0 – 50.4) 50.9 (50.3 – 51.4) 0.02
Birth Crown Rump Length (cm) 34.0 (33.8 – 34.1) 34.5 (34.1 – 35.0) 0.02
Birth Head Circumference (cm) 35.3 (35.1 – 35.4) 35.3 (35.0 – 35.7) 0.72
Birth Arm Circumference (cm) 11.1 (11.0 – 11.2) 11.2 (10.9 – 11.4) 0.66
Birth Triceps (cm) 4.8 (4.7 – 4.9) 4.9 (4.6 – 5.3) 0.54
Birth Sub Scapular (cm) 4.9 (4.8 – 5.1) 4.9 (4.6 – 5.3) 0.95
*No rare homozygotes were identified
Table 4: The effect of S19W maternal genotype on Fetal Growth:
Measurement SS (n = 400) SW/WW (n = 62)* P Value
Gestational Age (weeks) 40.11 (39.98 – 40.24) 40.19 (39.87 – 40.51) 0.66
Corrected Birth weight (grams) 3532.26 (3487.51 – 3577.02) 3504.533 (3391.55 – 3617.52) 0.65
Raw Birth weight (grams) 3550.36 (3505.43 – 3595.30) 3523.99 (3410.55 – 3637.42) 0.67
Birth Length (cm) 50.3 (50.1 – 50.5) 50.1 (49.6 – 50.6) 0.39
Birth Crown Rump Length (cm) 34.1 (33.9 – 34.2) 33.9 (33.5 – 34.3) 0.51
Birth Head Circumference (cm) 35.3 (35.1 – 35.7) 35.3 (35.0 – 35.6) 0.90
Birth Arm Circumference (cm) 11.1 (11.0 – 11.2) 11.1 (10.9 – 11.4) 0.77
Birth Triceps (cm) 4.8 (4.7 – 4.9) 4.9 (4.6 – 5.2) 0.46
Birth Sub Scapular (cm) 4.1 (4.8 – 5.0) 5.2 (4.9 – 5.5) 0.08
*Includes one rare homozygous subject
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raised triglycerides in pregnancy. Further studies are
needed to assess this as the size of the increase is modest
and the prevalence of clinical complications associated
with hypertriglyceridaemia in pregnancy rare.
Evidence so far indicates that the effect of ApoAV variants
on altering triglyceride concentrations is not lost or
reduced in hyperlipidaemic states. In addition to our
results in pregnancy, the -1131C allele was analysed in a
variety of dyslipidaemic conditions including hyperlipi-
daemia, hypoalphalipoproteinaemia and hyperalphali-
poproteinaemia from the University of California, San
Francisco (UCSF) Genomic Resource in Arteriosclerosis
and increased triglyceride and VLDL-Cholesterol concen-
trations by 10.7% and 24.2% respectively and marginally
reduced HDL-Cholesterol concentration by 4.9% [7]. The
-1131C allele was increased in frequency in hyperlipidae-
mia vs. control (13%) [7]. There was however no evidence
of an allelic association with either hypoalphalipoprotei-
naemia or hyperalphalipoproteinaemia [7].
Both of the variants investigated may have different func-
tional properties. The -1131T>C variant is in the promoter
region and is in linkage disequilibrium with a -3A>G var-
iant that is found in the 'kozak' region [13]. This -3A>G
variant disrupts a 6 to 8 bp sequence that precedes the ini-
tiation methionine and has been previously shown in
other genes to severely disrupt ribosomal translation effi-
ciency [13]. The S19W variant is in exon 2 and may cause
a variation in the signal sequence which would reduce
ApoAV secretion across the endoplasmic reticulum which
has been previously seen with the ApoB signal peptide
variant [13]. As ApoAV may act as a brake on the transport
of triglyceride rich lipoproteins from the liver, these vari-
ants would produce lower levels of ApoAV and therefore
increase the triglyceride plasma concentrations [13].
Variants in other genes that raise triglycerides are also
associated with raised triglycerides in pregnancy. In a
study on 250 pregnant Canadian women in their third tri-
mester, the presence of the e4/e4 polymorphism in the
ApoE gene increased triglyceride concentrations by 0.4
mmol/l (15%) compared to carriers of the e2/e2 variants.
Carriers of the S447X polymorphism in the LPL gene
showed a decrease of 0.6 mmol/l (21%) (P = 0.003) com-
pared to non-carriers and carriers of the N291S polymor-
phism showed an increase of 0.5 mmol/l (19%) (P = 0.2)
compared to non-carriers [1].
In addition to effects on triglyceride concentrations in
pregnancy we examined the role of maternal ApoAV geno-
type on fetal growth. Maternal triglyceride concentration
correlates strongly with birth weight and therefore genetic
effects on triglyceride concentrations in pregnancy could
contribute to fetal growth. We found evidence that the
presence of a maternal -1131T>C variant produces a 0.67
cm (1.3%) increase in birth length (p = 0.022) and a 0.57
cm (1.7%) increase in fetal birth crown to rump length (p
= 0.023). However, further studies will be needed to con-
firm or refute these observations.
Conclusions
In conclusion we have shown that variants in the ApoAV
gene raise 28-week pregnancy triglyceride concentration,
in addition to the triglyceride raising effect of pregnancy
itself. Preliminary evidence indicates that the gene is hav-
ing an effect on fetal growth parameters, but, this needs
replicating in further studies
Methods
Subjects
Genotyping was performed on 483 pregnant caucasian
females and their partners from the Exeter Family Study of
Childhood Health. These samples form part of an ongo-
ing study of parent-offspring trios. Women from the cen-
tral Exeter area were contacted at 25–26 weeks gestation
via letter and recruited via telephone one week later. Dur-
ing the 28th week of pregnancy, fasting venous blood sam-
ples were taken for biochemical and DNA isolation, as
were anthropometric measurements. Informed consent
was obtained from all subjects prior to samples and meas-
urements being taken.
A number of fasting blood biochemistries were measured
including insulin, glucose, triglycerides, total and HDL-
cholesterols, plus LDL-cholesterol (by calculation using
the Friedewald formula). All tests were performed in the
local Clinical Chemistry laboratory at the Royal Devon
and Exeter Hospital using dry slide technology on Vitros
950 analysers (Ortho Clinical) prior to December 2001
and manufacturers' standard reagents on Modular analys-
ers (Roche) thereafter. All local methods demonstrated
analytical Coefficients of Variation (CV's) of less than 5%.
Offspring of the mothers had detailed growth measure-
ments at birth, including weight, length, crown/rump
length, head circumference, arm circumference, triceps
skin fold and sub scapular skin fold. A sample of cord
blood was taken at delivery for DNA isolation.
Genotyping
Two ApoAV SNPs were used to define the two haplotypes
associated with raised triglyceride concentrations. These
were -1131T>C (SNP 3 in [6]) and S19W (c.56C>G in
[11]) which changes a Serine to a Tryptophan amino acid
at codon 19 [11].
Restriction Length Fragment Polymorphism (RFLP) anal-
ysis was used for both SNPs. The -1131T>C and S19W
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SNPs were genotyped as previously described ([6,11]
respectively) with the following exceptions:
For -1131T>C
The Polymerase Chain Reaction (PCR) was performed in
10 µl volume reactions containing in addition to the
standard reagents: 5 M Betaine, 5% DMSO due to the high
GC content of the target product, and 0.4 U of Amplitaq
Gold (Applied Biosystems, UK).
PCR cycling conditions were: denaturation at 95°C for 12
mins, followed by 40 cycles of denaturation at 95°C for 1
min, annealing at 54°C for 1 min and extension at 72°C
for 2 mins, with a final 10 min extension at 72°C.
The PCR was digested using 2 U of MseI (New England
Biolabs, UK) and incubated at 37°C overnight. The
digested product was run out on a 3% agarose gel for one
and a half hours at 200 V.
For S19W
The PCR was performed in a 10 µl volume reaction con-
taining in addition to the standard reagents: 0.4 U of
Amplitaq Gold (Applied Biosystems, UK).
PCR cycling conditions were: denaturation at 94°C for 12
mins followed by 34 cycles of denaturation at 94°C for 45
secs, annealing at 65°C for 45 secs and extension at 72°C
for 45 secs, with a final extension at 72°C for 10 mins.
The PCR product was digested using 7 U of EagI and incu-
bated at 37°C overnight. The digested product was run
out on a 3% agarose gel for one and a half hours at 200 V.
We performed extensive genotype quality control checks,
including confirming the presence of any rare homozy-
gotes by re-genotyping and sequencing, scoring gels on
two separate occasions and re-genotyping 10% of ran-
domly chosen samples. Overall genotyping results were
obtained in 94.5% of the samples and no errors in geno-
typing were detected.
Statistics
Hardy Weinberg Equilibrium for each SNP was tested by
comparing observed genotype numbers with expected
genotype numbers based on observed allele frequencies,
using a Chi-square analysis.
The LDMAX function of GOLD software was used to cal-
culate the Linkage Disequilibrium (LD) between the two
SNPs.
The correlation between maternal triglycerides, HDL-cho-
lesterol, LDL-cholesterol and measures of fetal growth
were calculated using regression analysis with SPSS.
The associations between the genotype of each SNP and
triglyceride concentrations were performed using univari-
ate general linear model analysis in SPSS. Each genotype
was looked at independently and samples that contained
at least one copy of the rare allele for the other SNP were
not included in the analysis. All non-normally distributed
data was log-transformed and back transformed geomet-
ric means and 95% Confidence Intervals are quoted.
Maternal anthropometry was uncorrected and maternal
biochemistry measures were corrected for weight (with
the exception of glucose that was corrected for age and
weight due to their significant effect on glucose).
Gestational age was corrected for sex and all other fetal
growth measurements were corrected for gestational age
and sex.
The comparison between pregnant female and male trig-
lyceride concentrations were determined using an Inde-
pendent T-Test.
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